A phase II study of RAD001 (everolimus) for children with chemotherapy hemotherapy-refractory progressive symptomatic low grade gliomas
Principal Investigator: Mark W. Kieran, MD, PhD
Initiative: Pediatric Low Grade Glioma (LGG) Initiative
Institute: Dana-Farber Cancer Institute
Location: Boston, MA